SCHEMBL20741191

SCHEMBL20741191

CC(C)(OC(N)=O)C(Cl)(Cl)Cl.CC(C)(OC(N)=O)c1ccc(-c2ccccc2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.40
KMT2A Q03164 1/20 0.40
CYP2C9 P11712 1/20 0.39
PTPN5 P54829 1/20 0.37
AKT1 P31749 1/20 0.37
AKT2 P31751 1/20 0.37
NPC1 O15118 1/20 0.37
LMNA P02545 1/20 0.37
CASP3 P42574 1/20 0.37
SENP8 Q96LD8 1/20 0.37
SENP7 Q9BQF6 1/20 0.37
SENP6 Q9GZR1 1/20 0.37
DHODH Q02127 1/20 0.36
PDCD1 Q15116 1/20 0.36
CD274 Q9NZQ7 1/20 0.36
ALDH1A1 P00352 1/20 0.35
ALOX15 P16050 1/20 0.35
KIF11 P52732 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.34
KDM4E B2RXH2 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL78396 0.89 MAPT (0.48) MAPTKMT2ACYP2C9PTPN5NPC1
SCHEMBL29658872 0.84 ADAMTS4 (0.40) MAPTKMT2ACYP2C9PTPN5AKT1
SCHEMBL112703 0.79 MAPT (0.55) MAPTKMT2AALDH1A1ALOX15KIF11
SCHEMBL20741189 0.79 MAPT (0.38) MAPTKMT2ACYP2C9PTPN5AKT1
SCHEMBL3290659 0.77 CYP2C9 (0.47) MAPTKMT2ACYP2C9PTPN5NPC1
SCHEMBL22323537 0.76 RXRA (0.50) MAPTKMT2APTPN5DHODHALDH1A1
SCHEMBL4070722 0.75 CYP2C9 (0.48) MAPTKMT2ACYP2C9PTPN5NPC1
Propane SCHEMBL28558464 0.75 MAPT (0.50) MAPTKMT2ALMNAALDH1A1ALOX15
SCHEMBL80733 0.74 LMNA (0.35) LMNAALOX15
SCHEMBL13839048 0.73 CYP2C9 (0.47) MAPTKMT2ACYP2C9PTPN5NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12491251-B2 Degraders of cyclin-dependent kinase 7 (CDK7) and uses thereof DANA-FARBER CANCER INSTITUTE, INC. (US) 2025-12-09 US disclosed
EP-4010336-B1 DEGRADERS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) AND USES THEREOF DANA FARBER CANCER INST INC (US) 2025-04-02 EP disclosed
US-20220280649-A1 DEGRADERS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-09-08 US disclosed
US-10870651-B2 Inhibitors of cyclin-dependent kinase 7 (CDK7) DANA-FARBER CANCER INSTITUTE, INC. (US) 2020-12-22 US disclosed
US-20190055248-A1 INHIBITORS OF CYCLINDEPENDENT KINASE 7 (CDK7) DANA-FARBER CANCER INSTITUTE, INC. 2019-02-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220280649-A1 DEGRADERS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) AND USES THEREOF CDK7, CDK8, CDK17 MAPT 1671/4885KMT2A 779/4885CYP2C9 2096/4885
US-12491251-B2 Degraders of cyclin-dependent kinase 7 (CDK7) and uses thereof CDK7, CDK8, CDK17 MAPT 1671/4885KMT2A 779/4885CYP2C9 2096/4885
US-20190055248-A1 INHIBITORS OF CYCLINDEPENDENT KINASE 7 (CDK7) CDK7, CDK3, CDK9 MAPT 172/4885KMT2A 886/4885CYP2C9 687/4885
US-10870651-B2 Inhibitors of cyclin-dependent kinase 7 (CDK7) CDK7, CDK3, CDK9 MAPT 265/4885KMT2A 1373/4885CYP2C9 502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.